The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration
There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long‐term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a surviva...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 66; no. 2; pp. 518 - 527 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.08.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long‐term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long‐term outcome. We identified 781 patients, median age 12 years, with 4,277 person‐years of follow‐up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event‐free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma‐glutamyltransferase, and aspartate aminotransferase‐to‐platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC–inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5‐0.9, and 0.7, 95% confidence interval 0.5‐0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long‐term outcome. Conclusion: PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma‐glutamyltransferase, and aspartate aminotransferase‐to‐platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC–inflammatory bowel disease are more favorable disease phenotypes. (Hepatology 2017;66:518–527). |
---|---|
AbstractList | There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long‐term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long‐term outcome. We identified 781 patients, median age 12 years, with 4,277 person‐years of follow‐up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event‐free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma‐glutamyltransferase, and aspartate aminotransferase‐to‐platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC–inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5‐0.9, and 0.7, 95% confidence interval 0.5‐0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long‐term outcome. Conclusion: PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma‐glutamyltransferase, and aspartate aminotransferase‐to‐platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC–inflammatory bowel disease are more favorable disease phenotypes. (Hepatology 2017;66:518–527). There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long-term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long-term outcome. We identified 781 patients, median age 12 years, with 4,277 person-years of follow-up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event-free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC-inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5-0.9, and 0.7, 95% confidence interval 0.5-0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long-term outcome. PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC-inflammatory bowel disease are more favorable disease phenotypes. (Hepatology 2017;66:518-527). There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long-term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long-term outcome. We identified 781 patients, median age 12 years, with 4,277 person-years of follow-up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event-free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC-inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5-0.9, and 0.7, 95% confidence interval 0.5-0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long-term outcome.CONCLUSIONPSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC-inflammatory bowel disease are more favorable disease phenotypes. (Hepatology 2017;66:518-527). There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long‐term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary complications, cholangiocarcinoma, liver transplantation, or death. We analyzed patients grouped by disease phenotype and laboratory studies at diagnosis to identify objective predictors of long‐term outcome. We identified 781 patients, median age 12 years, with 4,277 person‐years of follow‐up; 33% with autoimmune hepatitis, 76% with inflammatory bowel disease, and 13% with small duct PSC. Portal hypertensive and biliary complications developed in 38% and 25%, respectively, after 10 years of disease. Once these complications developed, median survival with native liver was 2.8 and 3.5 years, respectively. Cholangiocarcinoma occurred in 1%. Overall event‐free survival was 70% at 5 years and 53% at 10 years. Patient groups with the most elevated total bilirubin, gamma‐glutamyltransferase, and aspartate aminotransferase‐to‐platelet ratio index at diagnosis had the worst outcomes. In multivariate analysis PSC–inflammatory bowel disease and small duct phenotypes were associated with favorable prognosis (hazard ratios 0.6, 95% confidence interval 0.5‐0.9, and 0.7, 95% confidence interval 0.5‐0.96, respectively). Age, gender, and autoimmune hepatitis overlap did not impact long‐term outcome. Conclusion : PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma‐glutamyltransferase, and aspartate aminotransferase‐to‐platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC–inflammatory bowel disease are more favorable disease phenotypes. (H epatology 2017;66:518–527). |
Author | Vitola, Bernadette Valentino, Pamela L. Konidari, Anastasia Bazerbachi, Fateh Homan, Matjaz El‐Youssef, Mounif Ferrari, Federica Papadopoulou, Alexandra Amin, Mansi El‐Matary, Wael Iorio, Raffaele Miloh, Tamir Furuya, Katryn N. Vos, Miriam B. Ledder, Oren Ricciuto, Amanda Alqoaer, Khaled Shteyer, Eyal Woynarowski, Marek Auth, Marcus Chan, Albert Kim, Kyung Mo Saubermann, Lawrence Gottrand, Madeleine Cotter, Jillian Kolho, Kaija‐Leena Koot, Bart Deneau, Mark R. Martinez, Mercedes Mohan, Parvathi Smolka, Vratislav O'Cathain, Niamh Abdou, Reham Varier, Raghu Broderick, Annemarie Kamath, Binita M. Mack, Cara Gupta, Nitika Tanaka, Atushi Gottrand, Frederic Sathya, Pushpa Venkat, Veena Jensen, M. Kyle Yap, Jason Amir, Achiya Z. Doan, Sylvia |
Author_xml | – sequence: 1 givenname: Mark R. orcidid: 0000-0003-0459-9404 surname: Deneau fullname: Deneau, Mark R. email: mark.deneau@hsc.utah.edu organization: University of Utah – sequence: 2 givenname: Wael surname: El‐Matary fullname: El‐Matary, Wael organization: University of Manitoba – sequence: 3 givenname: Pamela L. surname: Valentino fullname: Valentino, Pamela L. organization: Yale University School of Medicine – sequence: 4 givenname: Reham surname: Abdou fullname: Abdou, Reham organization: State University of New York Buffalo – sequence: 5 givenname: Khaled surname: Alqoaer fullname: Alqoaer, Khaled organization: Prince Salman North West Armed Forces Hospital – sequence: 6 givenname: Mansi surname: Amin fullname: Amin, Mansi organization: University of California San Francisco, San Francisco, CA, and Texas Children's Hospital – sequence: 7 givenname: Achiya Z. surname: Amir fullname: Amir, Achiya Z. organization: The Tel‐Aviv Medical Center, Tel‐Aviv University – sequence: 8 givenname: Marcus surname: Auth fullname: Auth, Marcus organization: Alder Hey Children's Hospital – sequence: 9 givenname: Fateh surname: Bazerbachi fullname: Bazerbachi, Fateh organization: Mayo Clinic – sequence: 10 givenname: Annemarie surname: Broderick fullname: Broderick, Annemarie organization: University College Dublin – sequence: 11 givenname: Albert surname: Chan fullname: Chan, Albert organization: University of Rochester Medical Center – sequence: 12 givenname: Jillian surname: Cotter fullname: Cotter, Jillian organization: University of Colorado School of Medicine – sequence: 13 givenname: Sylvia surname: Doan fullname: Doan, Sylvia organization: University of Utah – sequence: 14 givenname: Mounif surname: El‐Youssef fullname: El‐Youssef, Mounif organization: Mayo Clinic – sequence: 15 givenname: Federica surname: Ferrari fullname: Ferrari, Federica organization: Sapienza University of Rome – sequence: 16 givenname: Katryn N. surname: Furuya fullname: Furuya, Katryn N. organization: Nemours Alfred I duPont Hospital For Children – sequence: 17 givenname: Madeleine surname: Gottrand fullname: Gottrand, Madeleine organization: Lille University Hospital of Lille – sequence: 18 givenname: Frederic surname: Gottrand fullname: Gottrand, Frederic organization: Lille University Hospital of Lille – sequence: 19 givenname: Nitika surname: Gupta fullname: Gupta, Nitika organization: Emory University School of Medicine – sequence: 20 givenname: Matjaz surname: Homan fullname: Homan, Matjaz organization: University of Ljubljana – sequence: 21 givenname: Binita M. surname: Kamath fullname: Kamath, Binita M. organization: University of Toronto – sequence: 22 givenname: Kyung Mo surname: Kim fullname: Kim, Kyung Mo organization: University of Ulsan – sequence: 23 givenname: Kaija‐Leena surname: Kolho fullname: Kolho, Kaija‐Leena organization: University of Helsinki – sequence: 24 givenname: Anastasia surname: Konidari fullname: Konidari, Anastasia organization: Liverpool, and University of Manchester – sequence: 25 givenname: Bart surname: Koot fullname: Koot, Bart organization: Academic Medical Centre – sequence: 26 givenname: Raffaele surname: Iorio fullname: Iorio, Raffaele organization: University of Naples Federico II – sequence: 27 givenname: Oren surname: Ledder fullname: Ledder, Oren organization: Shaare Zedek Medical Center – sequence: 28 givenname: Cara surname: Mack fullname: Mack, Cara organization: University of Colorado School of Medicine – sequence: 29 givenname: Mercedes surname: Martinez fullname: Martinez, Mercedes organization: Columbia University College of Physicians and Surgeons – sequence: 30 givenname: Tamir surname: Miloh fullname: Miloh, Tamir organization: Houston, TX, and Phoenix Children's Hospital – sequence: 31 givenname: Parvathi surname: Mohan fullname: Mohan, Parvathi organization: Children's National Medical Center – sequence: 32 givenname: Niamh surname: O'Cathain fullname: O'Cathain, Niamh organization: University College Dublin – sequence: 33 givenname: Alexandra surname: Papadopoulou fullname: Papadopoulou, Alexandra organization: University of Athens – sequence: 34 givenname: Amanda surname: Ricciuto fullname: Ricciuto, Amanda organization: University of Toronto – sequence: 35 givenname: Lawrence surname: Saubermann fullname: Saubermann, Lawrence organization: University of Rochester Medical Center – sequence: 36 givenname: Pushpa surname: Sathya fullname: Sathya, Pushpa organization: Memorial University – sequence: 37 givenname: Eyal surname: Shteyer fullname: Shteyer, Eyal organization: Shaare Zedek Medical Center – sequence: 38 givenname: Vratislav surname: Smolka fullname: Smolka, Vratislav organization: Palacky University – sequence: 39 givenname: Atushi surname: Tanaka fullname: Tanaka, Atushi organization: Teikyo University School of Medicine – sequence: 40 givenname: Raghu surname: Varier fullname: Varier, Raghu organization: Northwest Pediatric Gastroenterology LLC – sequence: 41 givenname: Veena surname: Venkat fullname: Venkat, Veena organization: University of Pittsburgh Medical Center – sequence: 42 givenname: Bernadette surname: Vitola fullname: Vitola, Bernadette organization: Medical College of Wisconsin – sequence: 43 givenname: Miriam B. surname: Vos fullname: Vos, Miriam B. organization: Emory University School of Medicine – sequence: 44 givenname: Marek surname: Woynarowski fullname: Woynarowski, Marek organization: Children's Health Memorial Institute – sequence: 45 givenname: Jason surname: Yap fullname: Yap, Jason organization: University of Alberta – sequence: 46 givenname: M. Kyle surname: Jensen fullname: Jensen, M. Kyle organization: University of Utah |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28390159$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU1LXDEUhoNY6qhd-Ack4MZCr54k9-bDnYitBUEXur5kcjNOJJOMyb2I_76nzrQLwdXJx8PD4X33yW7KyRNyxOCMAfDzpV-fccOh3SEz1nHVCNHBLpkBV9AYJswe2a_1GQBMy_VXsse1MMA6MyMvD0tPkx2nYiNdhjrm8kbzgq5LWFk8Vhd9yTWkJ-qWOdr0FMZQaUhUaYZPIQ7Fpwt6SVdTHIPzafTlB_7jQG3ICb0ux2jnubzfD8mXhY3Vf9vOA_L48_rh6qa5vfv1--rytnECRNtox9rOzqVrW7lQSrtOGckHye0wl621SmshhdNMD04xyzvpBg1caqfAgtHigJxuvOuSXyZfx34VqvO4SfJ5qj3TujMdkoDoyQf0OU-4fkQKYwWJYUmkvm8oh4HU4hf9NqSeQf-3hx576N97QPZ4a5zmKz_8J_8Fj8D5BngN0b99bupvru83yj_UE5Mb |
CitedBy_id | crossref_primary_10_1002_hep_31393 crossref_primary_10_3390_cancers15204947 crossref_primary_10_1007_s00384_023_04464_z crossref_primary_10_1093_ibd_izab120 crossref_primary_10_1016_j_eclinm_2024_102526 crossref_primary_10_1136_egastro_2023_100045 crossref_primary_10_1016_j_jpeds_2021_07_047 crossref_primary_10_1016_j_cgh_2018_01_020 crossref_primary_10_1002_cld_895 crossref_primary_10_1097_PG9_0000000000000220 crossref_primary_10_1016_j_mric_2019_01_007 crossref_primary_10_1002_hep_31702 crossref_primary_10_1097_MPG_0000000000002855 crossref_primary_10_1097_MPG_0000000000001801 crossref_primary_10_1016_j_ejrad_2018_10_006 crossref_primary_10_1097_HEP_0000000000000926 crossref_primary_10_1016_j_jhep_2017_07_022 crossref_primary_10_1002_hep_32771 crossref_primary_10_1002_hep_31560 crossref_primary_10_1016_j_jhep_2018_11_006 crossref_primary_10_1177_1066896918758451 crossref_primary_10_3138_canlivj_2021_0006 crossref_primary_10_1097_MPG_0000000000002050 crossref_primary_10_1111_liv_14159 crossref_primary_10_1111_liv_15007 crossref_primary_10_1002_hep_29882 crossref_primary_10_1111_liv_14831 crossref_primary_10_1080_17474124_2018_1521719 crossref_primary_10_1136_gutjnl_2018_317993 crossref_primary_10_3389_fimmu_2020_598152 crossref_primary_10_1097_MPG_0000000000003654 crossref_primary_10_1097_CLD_0000000000000006 crossref_primary_10_3748_wjg_v26_i21_2768 crossref_primary_10_1016_j_ajg_2021_05_009 crossref_primary_10_1016_j_cpsurg_2023_101377 crossref_primary_10_1080_17474124_2021_1900732 crossref_primary_10_33590_emjhepatol_10313935 crossref_primary_10_1016_j_pedneo_2021_08_001 crossref_primary_10_1016_j_dld_2021_06_028 crossref_primary_10_1016_j_jceh_2023_01_001 crossref_primary_10_1007_s11894_018_0620_2 crossref_primary_10_1002_hep4_1421 crossref_primary_10_1016_j_jaut_2018_10_008 crossref_primary_10_1097_MOP_0000000000001045 crossref_primary_10_1097_MPG_0000000000001789 crossref_primary_10_1007_s00247_018_4319_1 crossref_primary_10_3390_medicina57070663 crossref_primary_10_1136_gutjnl_2020_322362 crossref_primary_10_1097_MPG_0000000000003443 crossref_primary_10_1016_j_jhep_2022_05_011 crossref_primary_10_1016_j_ejrad_2020_109331 crossref_primary_10_1097_CLD_0000000000000020 crossref_primary_10_1016_j_jpeds_2019_01_039 crossref_primary_10_3389_fped_2021_634739 crossref_primary_10_1111_apt_17936 crossref_primary_10_3390_livers3010009 crossref_primary_10_3390_jcm8091481 crossref_primary_10_1016_j_crad_2019_05_018 crossref_primary_10_1007_s12016_019_08764_7 crossref_primary_10_1111_apt_14540 crossref_primary_10_1002_hsr2_1086 crossref_primary_10_4251_wjgo_v13_i10_1336 crossref_primary_10_1002_ueg2_12583 crossref_primary_10_3390_microorganisms11030597 crossref_primary_10_4254_wjh_v14_i5_944 crossref_primary_10_1002_hep4_1251 crossref_primary_10_3390_life14040500 crossref_primary_10_1016_j_jhepr_2024_101123 crossref_primary_10_1053_j_gastro_2021_07_046 crossref_primary_10_4254_wjh_v14_i5_945 crossref_primary_10_1016_j_jpeds_2021_09_011 crossref_primary_10_1016_j_jpeds_2021_09_012 crossref_primary_10_1016_j_cgh_2020_04_055 crossref_primary_10_1016_j_ejrad_2020_109101 crossref_primary_10_1111_hepr_13059 crossref_primary_10_1007_s00005_019_00550_9 crossref_primary_10_1016_j_jcmgh_2023_08_002 crossref_primary_10_1016_j_cgh_2019_07_011 crossref_primary_10_1080_00365521_2019_1648547 crossref_primary_10_1038_s41598_018_23870_w crossref_primary_10_1016_j_clinre_2018_03_011 crossref_primary_10_1016_j_jpeds_2019_07_065 crossref_primary_10_1016_j_jhep_2023_02_030 crossref_primary_10_1093_ibd_izad218 crossref_primary_10_32074_1591_951X_245 crossref_primary_10_3389_ti_2023_11729 crossref_primary_10_1093_ibd_izac003 crossref_primary_10_3390_pathogens12040585 crossref_primary_10_1016_j_pcl_2021_07_006 crossref_primary_10_1021_acs_analchem_1c03911 crossref_primary_10_1016_j_cld_2022_06_007 crossref_primary_10_1097_MPG_0000000000002522 crossref_primary_10_1016_j_pedneo_2021_05_001 crossref_primary_10_1097_MPG_0000000000002886 crossref_primary_10_1002_hep_31911 crossref_primary_10_2214_AJR_24_31108 crossref_primary_10_4254_wjh_v14_i3_495 crossref_primary_10_31146_1682_8658_ecg_209_1_165_177 crossref_primary_10_1093_ecco_jcc_jjad108 crossref_primary_10_1016_j_clinre_2022_101980 crossref_primary_10_1016_j_jhep_2023_03_017 crossref_primary_10_1007_s00247_020_04663_8 crossref_primary_10_1007_s11901_020_00518_w crossref_primary_10_1002_cld_672 crossref_primary_10_1016_j_dld_2023_05_024 crossref_primary_10_1016_j_jceh_2021_03_006 crossref_primary_10_1111_apt_17904 crossref_primary_10_1093_pch_pxae013 crossref_primary_10_1111_jpc_15954 crossref_primary_10_1002_hep_29208 crossref_primary_10_1007_s12072_018_9906_6 crossref_primary_10_1016_j_cgh_2020_08_006 crossref_primary_10_33590_emjhepatol_21_00172 crossref_primary_10_1002_hep4_1589 crossref_primary_10_1016_j_cld_2018_06_005 crossref_primary_10_4254_wjh_v11_i1_19 crossref_primary_10_55095_CSPediatrie2023_025 crossref_primary_10_1097_MPG_0000000000002035 crossref_primary_10_1016_j_cgh_2023_04_004 crossref_primary_10_1016_j_cgh_2019_08_048 crossref_primary_10_1007_s11901_017_0353_y crossref_primary_10_1016_j_jhep_2018_09_014 crossref_primary_10_1016_j_clinimag_2023_01_012 crossref_primary_10_1111_hepr_13421 crossref_primary_10_1002_hep4_1454 crossref_primary_10_1590_s0004_2803_202100000_41 crossref_primary_10_1111_hepr_13939 crossref_primary_10_4254_wjh_v14_i2_319 crossref_primary_10_1016_j_gtc_2020_07_001 crossref_primary_10_1016_j_pedneo_2018_09_007 crossref_primary_10_1186_s12876_019_1075_0 crossref_primary_10_1146_annurev_pathmechdis_031521_025623 crossref_primary_10_1016_j_cld_2022_03_009 crossref_primary_10_1186_s41927_021_00186_3 crossref_primary_10_21508_1027_4065_2021_66_5_150_156 |
Cites_doi | 10.1016/j.dld.2010.12.008 10.1038/ajg.2015.112 10.1002/hep.20029 10.1002/hep.23432 10.1111/j.1572-0241.2004.04067.x 10.1002/hep.26454 10.1016/S0168-8278(01)00251-3 10.1007/s10024-005-0020-0 10.1097/MCG.0b013e3181662426 10.1002/hep.23294 10.1053/j.gastro.2013.12.030 10.1053/j.gastro.2008.01.042 10.1111/j.1478-3231.2008.01726.x 10.1016/j.cgh.2008.10.019 10.1097/MEG.0b013e3283554bbf 10.1053/jhep.2003.50289 10.1136/gut.51.5.731 10.1016/S1499-3872(16)60088-7 10.1097/MPG.0b013e3182662233 10.5223/pghn.2015.18.4.268 10.1016/j.jhep.2008.08.013 10.1053/jhep.2002.33202 10.1002/hep.22441 10.1053/jhep.2003.50346 10.1016/S0025-6196(11)64614-4 10.1002/hep.23584 10.1016/j.crohns.2014.04.005 10.1002/jhbp.238 10.1002/hep.27825 10.1053/j.gastro.2013.06.052 10.1136/gut.38.4.610 10.1097/MCG.0b013e3182a87e78 10.1053/j.gastro.2004.11.018 10.1111/liv.12492 10.1016/j.cgh.2011.11.030 10.1097/MPG.0000000000001368 10.1053/jhep.2001.22131 10.1016/j.jhep.2012.10.013 |
ContentType | Journal Article |
Copyright | 2017 by the American Association for the Study of Liver Diseases. |
Copyright_xml | – notice: 2017 by the American Association for the Study of Liver Diseases. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
DOI | 10.1002/hep.29204 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1527-3350 |
EndPage | 527 |
ExternalDocumentID | 10_1002_hep_29204 28390159 HEP29204 |
Genre | article Multicenter Study Journal Article |
GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX ACLDA ACRPL ACYXJ ADNMO CITATION 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3034-8c145ab6c446f778c57962d62adb64aa788363c818dc71a256cd80268c70a0983 |
IEDL.DBID | DR2 |
ISSN | 0270-9139 |
IngestDate | Wed Dec 04 07:38:12 EST 2024 Thu Oct 10 17:28:13 EDT 2024 Fri Dec 06 07:16:23 EST 2024 Sat Sep 28 08:46:05 EDT 2024 Sat Aug 24 00:48:22 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | 2017 by the American Association for the Study of Liver Diseases. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3034-8c145ab6c446f778c57962d62adb64aa788363c818dc71a256cd80268c70a0983 |
Notes | See Editorial on Page Potential conflict of interest: Dr. Mohan received grants from Gilead. Dr. Auth received grants from AbbVie and Nutricia. Dr. Kamath consults for Retrophin. Dr. Miloh is on the speakers' bureau for Alexion. Dr. Vos consults and received grants from Shire. She consults for Intercept, Target, and Allergan. She received grants from Resonance. 315 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-0459-9404 |
OpenAccessLink | https://iris.uniroma1.it/bitstream/11573/974871/2/Deneau_Natural-history_2017.pdf |
PMID | 28390159 |
PQID | 1920069016 |
PQPubID | 996352 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1885950980 proquest_journals_1920069016 crossref_primary_10_1002_hep_29204 pubmed_primary_28390159 wiley_primary_10_1002_hep_29204_HEP29204 |
PublicationCentury | 2000 |
PublicationDate | August 2017 2017-08-00 20170801 |
PublicationDateYYYYMMDD | 2017-08-01 |
PublicationDate_xml | – month: 08 year: 2017 text: August 2017 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Hepatology (Baltimore, Md.) |
PublicationTitleAlternate | Hepatology |
PublicationYear | 2017 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2002; 36 2015; 18 2002; 51 2002; 35 2013; 145 2014; 48 2003; 38 1996; 38 2016; 15 2012; 55 2012; 10 2004; 99 2013; 58 2015; 62 2009; 50 2004; 39 2005; 8 1995; 22 2015; 22 2008; 28 2015; 110 2005; 128 2000; 75 2008; 48 2016; 63 2011; 43 2009; 7 2008; 42 2008; 134 2001; 33 2014; 8 2012; 24 2014; 34 2010; 51 2014; 146 28407274 - Hepatology. 2017 Aug;66(2):315-317 (hep29204-bib-0034-20241017) 2011; 43 (hep29204-bib-0038-20241017) 2014; 34 (hep29204-bib-0010-20241017) 2012; 10 (hep29204-bib-0018-20241017) 1996; 38 (hep29204-bib-0033-20241017) 2013; 58 (hep29204-bib-0002-20241017) 2016; 63 (hep29204-bib-0014-20241017) 2003; 38 (hep29204-bib-0031-20241017) 2000; 75 (hep29204-bib-0032-20241017) 2015; 22 (hep29204-bib-0013-20241017) 2012; 55 (hep29204-bib-0016-20241017) 2015; 62 (hep29204-bib-0006-20241017) 2009; 7 (hep29204-bib-0022-20241017) 2002; 36 (hep29204-bib-0009-20241017) 2010; 51 (hep29204-bib-0025-20241017) 2008; 48 (hep29204-bib-0003-20241017) 1995; 22 (hep29204-bib-0008-20241017) 2016; 15 (hep29204-bib-0012-20241017) 2010; 51 (hep29204-bib-0024-20241017) 2009; 50 (hep29204-bib-0037-20241017) 2002; 51 (hep29204-bib-0021-20241017) 2012; 24 (hep29204-bib-0001-20241017) 2013; 58 (hep29204-bib-0039-20241017) 2001; 33 (hep29204-bib-0019-20241017) 2010; 51 (hep29204-bib-0030-20241017) 2005; 128 (hep29204-bib-0005-20241017) 2005; 8 (hep29204-bib-0007-20241017) 2015; 18 (hep29204-bib-0017-20241017) 2008; 28 (hep29204-bib-0040-20241017) 2008; 42 (hep29204-bib-0029-20241017) 2014; 48 (hep29204-bib-0028-20241017) 2014; 146 (hep29204-bib-0035-20241017) 2002; 35 (hep29204-bib-0041-20241017) 2013; 145 (hep29204-bib-0004-20241017) 2003; 38 (hep29204-bib-0011-20241017) 2014; 8 (hep29204-bib-0023-20241017) 2004; 99 (hep29204-bib-0036-20241017) 2008; 134 (hep29204-bib-0026-20241017) 2015; 110 (hep29204-bib-0027-20241017) 2015; 62 (hep29204-bib-0020-20241017) 2004; 39 |
References_xml | – volume: 34 start-page: 1488 year: 2014 end-page: 1495 article-title: Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease publication-title: Liver Int – volume: 22 start-page: 1415 year: 1995 end-page: 1422 article-title: Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis publication-title: Hepatology – volume: 51 start-page: 660 year: 2010 end-page: 678 article-title: Diagnosis and management of primary sclerosing cholangitis publication-title: Hepatology – volume: 10 start-page: 417 year: 2012 end-page: 421 article-title: Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children publication-title: Clin Gastroenterol Hepatol – volume: 51 start-page: 731 year: 2002 end-page: 735 article-title: Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis publication-title: Gut – volume: 38 start-page: 610 year: 1996 end-page: 615 article-title: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis publication-title: Gut – volume: 145 start-page: 521 year: 2013 end-page: 536 article-title: Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management publication-title: Gastroenterology – volume: 28 start-page: 983 year: 2008 end-page: 989 article-title: Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis publication-title: Liver Int – volume: 58 start-page: 1392 year: 2013 end-page: 1400 article-title: Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history publication-title: Hepatology – volume: 33 start-page: 544 year: 2001 end-page: 553 article-title: Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16‐year prospective study publication-title: Hepatology – volume: 55 start-page: 340 year: 2012 end-page: 361 article-title: Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence‐based consensus guidelines publication-title: J Pediatr Gastroenterol Nutr – volume: 62 start-page: 246A year: 2015 article-title: Gender and IBD phenotype are independent predictors of death or transplantation and of malignancy in primary sclerosing cholangitis—a multicenter retrospective study of the International PSC Study Group (IPSCSG) [Abstract] publication-title: Hepatology – volume: 51 start-page: 1302 year: 2010 end-page: 1310 article-title: The predictors of the presence of varices in patients with primary sclerosing cholangitis publication-title: Hepatology – volume: 8 start-page: 568 year: 2005 end-page: 576 article-title: Primary sclerosing cholangitis in children: a histologic follow‐up study publication-title: Pediatr Dev Pathol – volume: 24 start-page: 1051 year: 2012 end-page: 1058 article-title: Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25‐year single‐centre experience publication-title: Eur J Gastroenterol Hepatol – volume: 58 start-page: 329 year: 2013 end-page: 334 article-title: Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis publication-title: J Hepatol – volume: 63 start-page: 603 year: 2016 end-page: 609 article-title: The natural history of primary sclerosing cholangitis in children: a large single center longitudinal cohort study publication-title: J Pediatr Gastroenterol Nutr – volume: 8 start-page: 1179 year: 2014 end-page: 1207 article-title: Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease publication-title: J Crohns Colitis – volume: 110 start-page: 646 year: 2015 end-page: 659 article-title: ACG clinical guideline: primary sclerosing cholangitis publication-title: Am J Gastroenterol – volume: 38 start-page: 518 year: 2003 end-page: 526 article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C publication-title: Hepatology – volume: 128 start-page: 343 year: 2005 end-page: 350 article-title: Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C publication-title: Gastroenterology – volume: 99 start-page: 523 year: 2004 end-page: 526 article-title: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis publication-title: Am J Gastroenterol – volume: 35 start-page: 1494 year: 2002 end-page: 1500 article-title: Small‐duct primary sclerosing cholangitis: a long‐term follow‐up study publication-title: Hepatology – volume: 15 start-page: 412 year: 2016 end-page: 418 article-title: Long‐term follow‐up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis publication-title: Hepatobiliary Pancreat Dis Int – volume: 38 start-page: 210 year: 2003 end-page: 217 article-title: Primary sclerosing cholangitis in children: a long‐term follow‐up study publication-title: Hepatology – volume: 7 start-page: 239 year: 2009 end-page: 245 article-title: A retrospective single‐center review of primary sclerosing cholangitis in children publication-title: Clin Gastroenterol Hepatol – volume: 22 start-page: 486 year: 2015 end-page: 490 article-title: Short‐term prognostic factors for primary sclerosing cholangitis publication-title: J Hepatobiliary Pancreat Sci – volume: 51 start-page: 2193 year: 2010 end-page: 2213 article-title: Diagnosis and management of autoimmune hepatitis publication-title: Hepatology – volume: 48 start-page: 370 year: 2014 end-page: 376 article-title: Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C publication-title: J Clin Gastroenterol – volume: 75 start-page: 688 year: 2000 end-page: 694 article-title: A revised natural history model for primary sclerosing cholangitis publication-title: Mayo Clin Proc – volume: 39 start-page: 204 year: 2004 end-page: 210 article-title: Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis publication-title: Hepatology – volume: 134 start-page: 975 year: 2008 end-page: 980 article-title: The natural history of small‐duct primary sclerosing cholangitis publication-title: Gastroenterology – volume: 42 start-page: 522 year: 2008 end-page: 526 article-title: A double‐blind, placebo‐controlled, randomized study of infliximab in primary sclerosing cholangitis publication-title: J Clin Gastroenterol – volume: 18 start-page: 268 year: 2015 end-page: 275 article-title: Primary sclerosing cholangitis with inflammatory bowel disease in Korean children publication-title: Pediatr Gastroenterol Hepatol Nutr – volume: 36 start-page: 151 year: 2002 end-page: 156 article-title: Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment publication-title: J Hepatol – volume: 48 start-page: 1106 year: 2008 end-page: 1117 article-title: Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis publication-title: Hepatology – volume: 50 start-page: 158 year: 2009 end-page: 164 article-title: High lifetime risk of cancer in primary sclerosing cholangitis publication-title: J Hepatol – volume: 62 start-page: 188 year: 2015 end-page: 197 article-title: Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis publication-title: Hepatology – volume: 146 start-page: 970 year: 2014 end-page: 979 article-title: Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis publication-title: Gastroenterology – volume: 43 start-page: 309 year: 2011 end-page: 313 article-title: Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis publication-title: Dig Liver Dis – volume: 43 start-page: 309 year: 2011 ident: hep29204-bib-0034-20241017 article-title: Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis publication-title: Dig Liver Dis doi: 10.1016/j.dld.2010.12.008 – volume: 110 start-page: 646 year: 2015 ident: hep29204-bib-0026-20241017 article-title: ACG clinical guideline: primary sclerosing cholangitis publication-title: Am J Gastroenterol doi: 10.1038/ajg.2015.112 – volume: 39 start-page: 204 year: 2004 ident: hep29204-bib-0020-20241017 article-title: Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.20029 – volume: 51 start-page: 1302 year: 2010 ident: hep29204-bib-0019-20241017 article-title: The predictors of the presence of varices in patients with primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.23432 – volume: 99 start-page: 523 year: 2004 ident: hep29204-bib-0023-20241017 article-title: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2004.04067.x – volume: 58 start-page: 1392 year: 2013 ident: hep29204-bib-0001-20241017 article-title: Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history publication-title: Hepatology doi: 10.1002/hep.26454 – volume: 36 start-page: 151 year: 2002 ident: hep29204-bib-0022-20241017 article-title: Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment publication-title: J Hepatol doi: 10.1016/S0168-8278(01)00251-3 – volume: 8 start-page: 568 year: 2005 ident: hep29204-bib-0005-20241017 article-title: Primary sclerosing cholangitis in children: a histologic follow‐up study publication-title: Pediatr Dev Pathol doi: 10.1007/s10024-005-0020-0 – volume: 42 start-page: 522 year: 2008 ident: hep29204-bib-0040-20241017 article-title: A double‐blind, placebo‐controlled, randomized study of infliximab in primary sclerosing cholangitis publication-title: J Clin Gastroenterol doi: 10.1097/MCG.0b013e3181662426 – volume: 51 start-page: 660 year: 2010 ident: hep29204-bib-0009-20241017 article-title: Diagnosis and management of primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.23294 – volume: 146 start-page: 970 year: 2014 ident: hep29204-bib-0028-20241017 article-title: Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.12.030 – volume: 134 start-page: 975 year: 2008 ident: hep29204-bib-0036-20241017 article-title: The natural history of small‐duct primary sclerosing cholangitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.01.042 – volume: 28 start-page: 983 year: 2008 ident: hep29204-bib-0017-20241017 article-title: Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis publication-title: Liver Int doi: 10.1111/j.1478-3231.2008.01726.x – volume: 7 start-page: 239 year: 2009 ident: hep29204-bib-0006-20241017 article-title: A retrospective single‐center review of primary sclerosing cholangitis in children publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2008.10.019 – volume: 24 start-page: 1051 year: 2012 ident: hep29204-bib-0021-20241017 article-title: Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25‐year single‐centre experience publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e3283554bbf – volume: 38 start-page: 210 year: 2003 ident: hep29204-bib-0004-20241017 article-title: Primary sclerosing cholangitis in children: a long‐term follow‐up study publication-title: Hepatology doi: 10.1053/jhep.2003.50289 – volume: 51 start-page: 731 year: 2002 ident: hep29204-bib-0037-20241017 article-title: Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis publication-title: Gut doi: 10.1136/gut.51.5.731 – volume: 15 start-page: 412 year: 2016 ident: hep29204-bib-0008-20241017 article-title: Long‐term follow‐up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis publication-title: Hepatobiliary Pancreat Dis Int doi: 10.1016/S1499-3872(16)60088-7 – volume: 55 start-page: 340 year: 2012 ident: hep29204-bib-0013-20241017 article-title: Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence‐based consensus guidelines publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/MPG.0b013e3182662233 – volume: 18 start-page: 268 year: 2015 ident: hep29204-bib-0007-20241017 article-title: Primary sclerosing cholangitis with inflammatory bowel disease in Korean children publication-title: Pediatr Gastroenterol Hepatol Nutr doi: 10.5223/pghn.2015.18.4.268 – volume: 50 start-page: 158 year: 2009 ident: hep29204-bib-0024-20241017 article-title: High lifetime risk of cancer in primary sclerosing cholangitis publication-title: J Hepatol doi: 10.1016/j.jhep.2008.08.013 – volume: 35 start-page: 1494 year: 2002 ident: hep29204-bib-0035-20241017 article-title: Small‐duct primary sclerosing cholangitis: a long‐term follow‐up study publication-title: Hepatology doi: 10.1053/jhep.2002.33202 – volume: 48 start-page: 1106 year: 2008 ident: hep29204-bib-0025-20241017 article-title: Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.22441 – volume: 38 start-page: 518 year: 2003 ident: hep29204-bib-0014-20241017 article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C publication-title: Hepatology doi: 10.1053/jhep.2003.50346 – volume: 75 start-page: 688 year: 2000 ident: hep29204-bib-0031-20241017 article-title: A revised natural history model for primary sclerosing cholangitis publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)64614-4 – volume: 51 start-page: 2193 year: 2010 ident: hep29204-bib-0012-20241017 article-title: Diagnosis and management of autoimmune hepatitis publication-title: Hepatology doi: 10.1002/hep.23584 – volume: 8 start-page: 1179 year: 2014 ident: hep29204-bib-0011-20241017 article-title: Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2014.04.005 – volume: 62 start-page: 246A year: 2015 ident: hep29204-bib-0016-20241017 article-title: Gender and IBD phenotype are independent predictors of death or transplantation and of malignancy in primary sclerosing cholangitis—a multicenter retrospective study of the International PSC Study Group (IPSCSG) [Abstract] publication-title: Hepatology – volume: 22 start-page: 486 year: 2015 ident: hep29204-bib-0032-20241017 article-title: Short‐term prognostic factors for primary sclerosing cholangitis publication-title: J Hepatobiliary Pancreat Sci doi: 10.1002/jhbp.238 – volume: 62 start-page: 188 year: 2015 ident: hep29204-bib-0027-20241017 article-title: Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.27825 – volume: 145 start-page: 521 year: 2013 ident: hep29204-bib-0041-20241017 article-title: Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.06.052 – volume: 38 start-page: 610 year: 1996 ident: hep29204-bib-0018-20241017 article-title: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis publication-title: Gut doi: 10.1136/gut.38.4.610 – volume: 48 start-page: 370 year: 2014 ident: hep29204-bib-0029-20241017 article-title: Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C publication-title: J Clin Gastroenterol doi: 10.1097/MCG.0b013e3182a87e78 – volume: 128 start-page: 343 year: 2005 ident: hep29204-bib-0030-20241017 article-title: Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.11.018 – volume: 34 start-page: 1488 year: 2014 ident: hep29204-bib-0038-20241017 article-title: Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease publication-title: Liver Int doi: 10.1111/liv.12492 – volume: 10 start-page: 417 year: 2012 ident: hep29204-bib-0010-20241017 article-title: Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2011.11.030 – volume: 63 start-page: 603 year: 2016 ident: hep29204-bib-0002-20241017 article-title: The natural history of primary sclerosing cholangitis in children: a large single center longitudinal cohort study publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/MPG.0000000000001368 – volume: 33 start-page: 544 year: 2001 ident: hep29204-bib-0039-20241017 article-title: Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16‐year prospective study publication-title: Hepatology doi: 10.1053/jhep.2001.22131 – volume: 22 start-page: 1415 year: 1995 ident: hep29204-bib-0003-20241017 article-title: Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis publication-title: Hepatology – volume: 58 start-page: 329 year: 2013 ident: hep29204-bib-0033-20241017 article-title: Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis publication-title: J Hepatol doi: 10.1016/j.jhep.2012.10.013 |
SSID | ssj0009428 |
Score | 2.6238725 |
Snippet | There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 518 |
SubjectTerms | Analysis of Variance Aspartate aminotransferase Bilirubin Biopsy, Needle Child Children Cholangiocarcinoma Cholangitis Cholangitis, Sclerosing - mortality Cholangitis, Sclerosing - pathology Cholangitis, Sclerosing - surgery Cohort Studies Confidence intervals Disease Progression Disease-Free Survival Female Follow-Up Studies Hepatitis Hepatology Humans Hypertension Immunohistochemistry Inflammatory bowel disease Inflammatory bowel diseases Internationality Intestine Japan Liver Liver Function Tests Liver transplantation Liver Transplantation - methods Liver Transplantation - mortality Male Medical prognosis Multivariate Analysis Pediatrics Predictive Value of Tests Proportional Hazards Models Retrospective Studies Risk Assessment Severity of Illness Index Survival Survival Analysis Transplantation γ-Glutamyltransferase |
Title | The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.29204 https://www.ncbi.nlm.nih.gov/pubmed/28390159 https://www.proquest.com/docview/1920069016 https://search.proquest.com/docview/1885950980 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFH8MD-LF74_qlCgePNitn2mqp6EbQ5iIONhBKEna4hC6uW4H_et9SdvNKYJ4KzQhH--95PeSl98DOLcdGnu29E3EQgk6KK5rChmnZsAtETOLx55O39a7p92-dzfwBzW4rt7CFPwQ8wM3ZRl6vVYGzkXeXJCGviTjhkq1pLhAbTdQ4Xy3jwvqqNDTeVXR67LU7XJYsQpZTnNec3kv-gEwl_Gq3nA6G_BcdbWIM3ltzKaiIT--sTj-cyybsF4CUdIqNGcLakm2Dau98qp9B95QgYim_cRSBSvxOxmlZFzQU5Aca-GocOcj2j9WeY-GORlmJGA2qd6IX5EW0TGLKgg0mVyS4dcTSLKkhbvQ77SfbrpmmZ_BlLjxeSaTtudzQSW6lGkQMKnetToxdXgsqMc5etcudSVCglgGNkdwJVH8DmUysLgVMncPVrJRlhwACQNL4OqRcoo1Q0aZjzCT2yIRqedK6RtwVkkqKscZFYTLToSTF-nJM6BeyTAqLTGPEMFqNmabGnA6_402pC5GeJaMZliGKZY37JFlwH4h-3krCL8UZAoNuNAS_L35qNt-0B-Hfy96BGuOwgk6orAOK9PJLDlGlDMVJ1qdPwG8wfdR |
link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8QwEB50BfXF-6hnFB98sGuPNE3FF_FgPVZEFHyRkqQtLkJX93jQX-8kbVdXEcS3QhNyzEzyTTL5BmDH9VhCXRXYiIVSdFB835YqyexQODLhjkioSd_WvGaNe3rxEDyMwGH1FqbghxgcuGnLMOu1NnB9IL3_yRr6lL7Uda4lOgpjaO6uDug6uf0kj4qoyayKfpej75ejilfI8fYHVYd3ox8Qcxixmi3nbBoeq84WkSbP9X5P1tX7Nx7H_45mBqZKLEqOCuWZhZE0n4PxZnnbPg-vqEPEMH9iqYKY-I20M_JSMFSQLtbCYeHmR4yLrFMftbqklZOQu6R6Jn5AjogJW9RxoGlnj7S-HkKSIUVcgPuz07vjhl2maLAV7n3U5sqlgZBMoVeZhSFX-mmrlzBPJJJRIdDB9pmvEBUkKnQF4iuFGuAxrkJHOBH3F6GWt_N0GUgUOhIXkEwwrBlxxgNEmsKVqcyor1RgwXYlqrgcZ1xwLnsxTl5sJs-CtUqIcWmM3RhBrCFkdpkFW4PfaEb6bkTkabuPZbgmesMeORYsFcIftIIITKOmyIJdI8Lfm48bpzfmY-XvRTdhonHXvIqvzq8vV2HS07DBBBiuQa3X6afrCHp6csPo9gc_Xfty |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8QwEB48QHzxPuoZxQcf7NojTVN9WtRlPRFR8EEoSdriInRXd_dBf72TtN11FUF8KzQhx8wk3ySTbwD2XI8l1FWBjVgoRQfF922pkswOhSMT7oiEmvRt1zes-UAvHoPHMTiu3sIU_BCDAzdtGWa91gbeSbLDIWnoc9qp6VRLdBwmKfMiTZx_ejfkjoqoSayKbpejr5ejilbI8Q4HVUc3ox8IcxSwmh2nMQtPVV-LQJOXWr8na-rjG43jPwczBzMlEiX1QnXmYSzNF2DqurxrX4RX1CBieD-xVEFL_E7aGekU_BSki7VwVLj1EeMg68RHrS5p5STkLqkeiR-ROjFBizoKNH07IK2vR5BkRA2X4KFxdn_StMsEDbbCnY_aXLk0EJIp9CmzMORKP2z1EuaJRDIqBLrXPvMVYoJEha5AdKVQ_h7jKnSEE3F_GSbydp6uAolCR-LykQmGNSPOeIA4U7gylRn1lQos2K0kFZfjjAvGZS_GyYvN5FmwUckwLk2xGyOENXTMLrNgZ_AbjUjfjIg8bfexDNc0b9gjx4KVQvaDVhB_acwUWbBvJPh783Hz7NZ8rP296DZM3Z424qvzm8t1mPY0ZjDRhRsw0Xvrp5uIeHpyy2j2J1Qn-iE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+natural+history+of+primary+sclerosing+cholangitis+in+781+children%3A+A+multicenter%2C+international+collaboration&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Deneau%2C+Mark+R&rft.au=El-Matary%2C+Wael&rft.au=Valentino%2C+Pamela+L&rft.au=Abdou%2C+Reham&rft.date=2017-08-01&rft.eissn=1527-3350&rft.volume=66&rft.issue=2&rft.spage=518&rft_id=info:doi/10.1002%2Fhep.29204&rft_id=info%3Apmid%2F28390159&rft.externalDocID=28390159 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |